Tag: Zydus
Zydus Therapeutics announces positive phase 2b/3 results for Saroglitazar in primary...
EPICS-III trial met primary and key secondary endpoints, with Saroglitazar demonstrating significant efficacy, good tolerability, and paving the way for a planned U.S. regulatory submission in early 2026
New flu vaccine guidelines put spotlight on India’s low coverage
Experts at Zydus event warn of rising influenza burden, urge wider immunisation of vulnerable groups
Zydus Lifesciences posts 6% revenue growth in Q1 FY26, Net profit...
Strong performance in chronic therapies, robust international growth, and strategic acquisitions bolster the company’s innovation pipeline and global presence
Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S....
This acquisition positions Zydus at the forefront of the fast-growing global biologics CDMO market, establishing a robust presence in the world’s leading biotech innovation hub
Zydus Lifesciences completes 25 years of listing on NSE, commemorated with...
Over the last 24 years, the Company's sales has grown from Rs 478 crores to Rs 19,022 crores, a CAGR of 17%
Zydus signs purchase agreement with PAI Partners & others to acquire...
Subject to the fulfilment of the closing conditions, Zydus will acquire 85.6% of the share capital of Amplitude
Zydus Medtech and Braile Biomedica of Brazil announce global licensing pact...
The company gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
Zydus to develop world’s first combination vaccine against shigellosis & typhoid...
The project is expected to get underway in March 2025, and is being supported by the Gates Foundation
Zydus & Beihai Biotech sign an exclusive deal to commercialize BEIZRAY...
Beihai Biotech shall receive upfront payments, sales targets-based milestone payments and a share of BEIZRAY’s net profits earned in the US as per the terms of the agreement
Zydus Life net profit up 30% to Rs 1,024 crore, revenue...
The company’s revenue from operations stood at Rs 5,269 crore, up 17% as compared to Rs 4,505 crore reported in Q3 FY24